Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Taiwan Speciality Chemicals Corporation (4772.TWO)
Changhua, TW
Taiwan Speciality Chemicals Corporation is a Taiwanese enterprise dedicated to the production and supply of specialized electronic-grade gases and chemicals. Its product portfolio features key offerings such as disilane, trisilane, and a variety of related silicon compounds. The company, established in 2013, is headquartered in Changhua, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.90% | -0.64% | +4.39% | -5.79% | +0.32% | -2.22% | +61.78% | +295.65% | +129.74% | +129.74% | +129.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | -1 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+127.9% ★ Q1'26: +290.0% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+52.4% ★ Q1'26: +90.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+35.5% ★ Q1'26: +27.9% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+42.5% ★ Q1'26: +40.2% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+15.7% ★ Q1'26: +25.6% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+6.4% Q1'26: +36.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×2.15× ★ Q1'26: 1.33× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|
| Revenue |
1.99B
est: 1.97B (+1.1%)
|
3.83B
3.62B – 4.03B
+94.5% YoY
|
4.84B
4.77B – 4.93B
+26.2% YoY
|
| EBITDA |
971.33M
est: 1.09B (-10.8%)
|
2.12B
2.00B – 2.23B
+94.5% YoY
|
2.67B
2.64B – 2.73B
+26.2% YoY
|
| EBIT |
846.73M
est: 729.85M (+16.0%)
|
1.42B
1.34B – 1.49B
+94.5% YoY
|
1.79B
1.77B – 1.83B
+26.2% YoY
|
| Net Income |
620.07M
est: 623.51M (-0.6%)
|
1.08B
1.06B – 1.09B
+72.7% YoY
|
1.45B
1.43B – 1.48B
+35.1% YoY
|
| SGA |
158.69M
est: 183.99M (-13.8%)
|
357.89M
337.69M – 376.74M
+94.5% YoY
|
451.80M
445.78M – 460.69M
+26.2% YoY
|
| EPS |
4.20
est: 4.15 (+1.2%)
|
7.18
7.08 – 7.28
+72.9% YoY
|
9.69
9.51 – 9.88
+35.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.07% | 50.4K | 0.74% |
| 2 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.06% | 68.4K | 0.42% |
| 3 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.05% | 177.8K | 0.72% |
| 4 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.04% | 142.8K | 0.74% |
| 5 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.03% | 193.1K | 0.55% |
| 6 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 2.64M | 0.06% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 201.6K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.01% | 89.4K | 0.48% |
| 9 | iShares Core MSCI EM IMI UCITS ETF EIMU.L | 0.01% | 109.7K | 0.18% |
| 10 | iShares Core MSCI EM IMI UCITS ETF EIMI.L | 0.01% | 2.67M | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hsiung-Fei Chang | GM & Head of Sales Office | — | male |
| Jie Che Liao | Director of Accounting Department & Head of Corporate Governance | — | male |
| Yu Li Ke | Chief of Administrative Department & Head of Quality Assurance Center | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4772.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
